CRMD Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-09-13 | 2022 | Joseph Todisco | 378,461 | 0 | 701,245 | 305,760 | 32,223 | 2,691,189 |
| 2023-09-13 | 2021 | Thomas Nusbickel Former Chief Commercial Officer | 233,654 | 75,000 | 0 | 0 | 27,663 | 1,876,582 |
| 2023-09-13 | 2022 | Thomas Nusbickel Former Chief Commercial Officer | 191,827 | 0 | 0 | 31,384 | 416,766 | 945,877 |
| 2023-09-13 | 2021 | Elizabeth Hurlburt Executive Vice President and Head of Clinical Operations | 310,800 | 37,800 | 0 | 0 | 44,818 | 1,136,328 |
| 2023-09-13 | 2022 | Elizabeth Hurlburt Executive Vice President and Head of Clinical Operations | 346,346 | 0 | 0 | 175,623 | 16,942 | 844,811 |
| 2023-09-13 | 2021 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375,000 | 61,875 | 0 | 0 | 11,412 | 1,613,097 |
| 2023-09-13 | 2022 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375,000 | 0 | 0 | 195,075 | 12,146 | 1,010,481 |
| 2023-09-13 | 2021 | Matthew David Executive Vice President and Chief Financial Officer | 351,923 | 75,900 | 0 | 0 | 43,584 | 1,423,302 |
| 2023-09-13 | 2022 | Matthew David Executive Vice President and Chief Financial Officer | 393,462 | 0 | 0 | 389,485 | 47,697 | 1,136,544 |
| 2022-08-30 | 2020 | John Armstrong Former Executive Vice President for Technical Operations | 322,635 | 0 | 0 | 112,875 | 19,388 | 787,318 |
| 2022-08-30 | 2021 | Matthew David Executive Vice President and Chief Financial Officer | 351,923 | 75,900 | 0 | 0 | 43,584 | 1,423,302 |
| 2022-08-30 | 2020 | Matthew David Executive Vice President and Chief Financial Officer | 209,423 | 0 | 0 | 99,000 | 20,866 | 1,097,675 |
| 2022-08-30 | 2021 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 310,800 | 37,800 | 0 | 0 | 44,818 | 1,136,328 |
| 2022-08-30 | 2020 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations | 350,000 | 0 | 0 | 163,333 | 9,745 | 931,148 |
| 2022-08-30 | 2021 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations | 375,000 | 61,875 | 0 | 0 | 11,412 | 1,613,097 |
| 2022-08-30 | 2021 | Thomas Nusbickel | 233,654 | 75,000 | 0 | 0 | 27,663 | 1,876,582 |
| 2022-08-30 | 2020 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 291,792 | 0 | 0 | 136,500 | 35,561 | 796,273 |
| 2022-08-30 | 2021 | Khoso Baluch Former Chief Executive Officer | 366,700 | 0 | 0 | 0 | 531,393 | 2,596,173 |
| 2022-08-30 | 2020 | Khoso Baluch Former Chief Executive Officer | 425,000 | 0 | 0 | 340,000 | 40,088 | 1,233,671 |
| 2022-08-30 | 2021 | John Armstrong Former Executive Vice President for Technical Operations | 272,500 | 0 | 0 | 0 | 323,938 | 1,339,348 |
| 2021-10-29 | 2020 | Robert W. Cook | 242,403 | 0 | 0 | 0 | 2,615 | 245,018 |
| 2021-10-29 | 2020 | Khoso Baluch Chief Executive Officer | 425,000 | 0 | 0 | 340,000 | 40,088 | 1,233,671 |
| 2021-10-29 | 2019 | Khoso Baluch Chief Executive Officer | 387,885 | 0 | 0 | 248,000 | 26,344 | 1,795,829 |
| 2021-10-29 | 2019 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 280,000 | 0 | 0 | 67,200 | 25,734 | 671,438 |
| 2021-10-29 | 2020 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 291,792 | 0 | 0 | 136,500 | 35,561 | 796,273 |
| 2021-10-29 | 2019 | John Armstrong Executive Vice President for Technical Operations | 310,000 | 0 | 0 | 86,800 | 11,001 | 464,996 |
| 2021-10-29 | 2020 | John Armstrong Executive Vice President for Technical Operations | 322,635 | 0 | 0 | 112,875 | 19,388 | 787,318 |
| 2021-10-29 | 2019 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 232,885 | 0 | 0 | 84,000 | 2,479 | 746,154 |
| 2021-10-29 | 2020 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 350,000 | 0 | 0 | 163,333 | 9,745 | 931,148 |
| 2021-10-29 | 2019 | Matthew David Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-10-29 | 2020 | Matthew David Chief Financial Officer | 209,423 | 0 | 0 | 99,000 | 20,866 | 1,097,675 |
| 2020-11-04 | 2018 | Robert W. Cook Chief Financial Officer | 350,000 | 0 | 0 | 84,000 | 23,546 | 457,546 |
| 2020-11-04 | 2018 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 277,245 | 0 | 0 | 56,000 | 21,723 | 420,478 |
| 2020-11-04 | 2019 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 280,000 | 0 | 0 | 67,200 | 25,734 | 671,438 |
| 2020-11-04 | 2018 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-11-04 | 2019 | Khoso Baluch Chief Executive Officer | 387,885 | 0 | 0 | 248,000 | 26,344 | 1,795,829 |
| 2020-11-04 | 2018 | Khoso Baluch Chief Executive Officer | 375,000 | 0 | 0 | 240,000 | 22,841 | 637,841 |
| 2020-11-04 | 2019 | Robert W. Cook Chief Financial Officer | 350,000 | 0 | 0 | 0 | 20,763 | 497,863 |
| 2020-11-04 | 2019 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 232,885 | 0 | 0 | 84,000 | 2,479 | 746,154 |
| 2020-11-04 | 2018 | John Armstrong Executive Vice President for Technical Operations | 312,308 | 0 | 0 | 86,800 | 0 | 399,108 |
| 2020-11-04 | 2019 | John Armstrong Executive Vice President for Technical Operations | 310,000 | 0 | 0 | 86,800 | 11,001 | 464,996 |
| 2019-10-17 | 2018 | Robert W. Cook Chief Financial Officer | 350,000 | 0 | 0 | 84,000 | 23,546 | 457,546 |
| 2019-10-17 | 2017 | Robert W. Cook Chief Financial Officer | 320,385 | 0 | 0 | 60,638 | 24,273 | 861,241 |
| 2019-10-17 | 2018 | John Armstrong Executive Vice President for Technical Operations | 312,308 | 0 | 0 | 86,800 | 0 | 399,108 |
| 2019-10-17 | 2017 | John Armstrong Executive Vice President for Technical Operations | 341,056 | 0 | 78,604 | 56,963 | 0 | 643,643 |
| 2019-10-17 | 2018 | Elizabeth Masson Executive Vice President and Head of Clinical Operations | 277,345 | 0 | 0 | 56,000 | 21,723 | 420,478 |
| 2019-10-17 | 2017 | Elizabeth Masson Executive Vice President and Head of Clinical Operations | 2,800 | 0 | 0 | 0 | 0 | 2,800 |
| 2019-10-17 | 2018 | Khoso Baluch Chief Executive Officer | 375,000 | 0 | 0 | 240,000 | 22,841 | 637,841 |
| 2019-10-17 | 2017 | Khoso Baluch Chief Executive Officer | 375,000 | 0 | 0 | 189,000 | 68,533 | 632,533 |
| 2018-11-01 | 2017 | Khoso Baluch Chief Executive Officer | 375,000 | 0 | 0 | 189,474 | 68,533 | 633,007 |
| 2018-11-01 | 2016 | James Altland Interim Chief Financial Officer | 244,485 | 0 | 0 | 0 | 0 | 244,485 |
| 2018-11-01 | 2016 | Robert W. Cook Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-11-01 | 2017 | James Altland Interim Chief Financial Officer | 57,100 | 0 | 0 | 0 | 0 | 57,100 |
| 2018-11-01 | 2016 | Judith Abrams Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-11-01 | 2017 | Judith Abrams Chief Medical Officer | 346,733 | 0 | 0 | 0 | 15,448 | 818,126 |
| 2018-11-01 | 2016 | John Armstrong Executive Vice President for | 335,400 | 0 | 0 | 0 | 0 | 1,486,155 |
| 2018-11-01 | 2016 | Khoso Baluch Chief Executive Officer | 93,750 | 0 | 0 | 75,000 | 39,574 | 3,394,774 |
| 2018-11-01 | 2017 | Robert W. Cook Chief Financial Officer | 320,385 | 0 | 0 | 60,789 | 24,273 | 861,392 |
| 2018-11-01 | 2017 | John Armstrong Executive Vice President for | 341,056 | 0 | 78,604 | 57,105 | 0 | 643,785 |
| 2017-04-24 | 2014 | Antony E. Pfaffle Chief Scientific Officer | 219,800 | 0 | 0 | 30,000 | 16,928 | 623,728 |
| 2017-04-24 | 2016 | Khoso Baluch Chief Executive Officer | 93,750 | 0 | 0 | 75,000 | 39,574 | 3,394,774 |
| 2017-04-24 | 2015 | Khoso Baluch Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-24 | 2014 | Khoso Baluch Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-24 | 2016 | Randy Milby Chief Executive Officer | 308,746 | 0 | 0 | 112,500 | 30,818 | 452,064 |
| 2017-04-24 | 2015 | Randy Milby Chief Executive Officer | 300,000 | 0 | 0 | 150,000 | 4,715 | 723,740 |
| 2017-04-24 | 2014 | Randy Milby Chief Executive Officer | 287,500 | 0 | 0 | 0 | 0 | 435,000 |
| 2017-04-24 | 2016 | Antony E. Pfaffle Chief Scientific Officer | 275,962 | 0 | 0 | 0 | 26,641 | 302,603 |
| 2017-04-24 | 2015 | Antony E. Pfaffle Chief Scientific Officer | 250,000 | 0 | 0 | 75,000 | 6,694 | 600,719 |
| 2017-04-24 | 2016 | James Altland Interim Chief Financial Officer | 244,485 | 0 | 0 | 0 | 0 | 244,485 |
| 2017-04-24 | 2015 | James Altland Interim Chief Financial Officer | 60,666 | 0 | 0 | 0 | 0 | 60,666 |
| 2017-04-24 | 2014 | James Altland Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-05-04 | 2014 | James Altland Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-05-04 | 2015 | Randy Milby Chief Executive Officer | 300,000 | 0 | 0 | 150,000 | 4,715 | 723,740 |
| 2016-05-04 | 2014 | Randy Milby Chief Executive Officer | 287,500 | 0 | 0 | 0 | 0 | 435,000 |
| 2016-05-04 | 2015 | Antony E. Pfaffle Chief Scientific Officer | 250,000 | 0 | 0 | 75,000 | 6,694 | 600,719 |
| 2016-05-04 | 2014 | Antony E. Pfaffle Chief Scientific Officer | 219,800 | 0 | 0 | 30,000 | 16,928 | 623,728 |
| 2016-05-04 | 2015 | Harry O’Grady Chief Financial Officer | 182,968 | 0 | 0 | 73,600 | 3,637 | 260,205 |
| 2016-05-04 | 2014 | Harry O’Grady Chief Financial Officer | 103,795 | 0 | 0 | 0 | 0 | 214,795 |
| 2016-05-04 | 2015 | James Altland Interim Chief Financial Officer | 60,666 | 0 | 0 | 0 | 0 | 60,666 |
| 2015-04-22 | 2014 | Harry O’Grady Chief Financial Officer | 103,795 | 0 | 0 | 0 | 0 | 214,795 |
| 2015-04-22 | 2014 | Randy Milby Chief Executive Officer | 287,500 | 0 | 0 | 0 | 0 | 435,000 |
| 2015-04-22 | 2013 | Randy Milby Chief Executive Officer | 223,500 | 0 | 0 | 0 | 0 | 592,000 |
| 2015-04-22 | 2014 | Steven W. Lefkowitz Interim Chief Financial Officer | 60,000 | 0 | 0 | 0 | 26,483 | 425,733 |
| 2015-04-22 | 2013 | Steven W. Lefkowitz Interim Chief Financial Officer | 30,000 | 0 | 0 | 0 | 39,650 | 158,090 |
| 2015-04-22 | 2014 | Antony E. Pfaffle Acting Chief Scientific Officer | 219,800 | 30,000 | 0 | 0 | 16,928 | 623,728 |
| 2015-04-22 | 2013 | Antony E. Pfaffle Acting Chief Scientific Officer | 120,000 | 0 | 0 | 0 | 37,500 | 312,270 |
| 2015-04-22 | 2013 | Harry O’Grady Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-05-16 | 2012 | Randy Milby Chief Executive Officer | 58,800 | 0 | 0 | 0 | 0 | 126,550 |
| 2014-05-16 | 2012 | Antony E. Pfaffle Acting Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-05-16 | 2013 | Antony E. Pfaffle Acting Chief Scientific Officer | 120,000 | 0 | 0 | 0 | 37,500 | 312,270 |
| 2014-05-16 | 2012 | Steven W. Lefkowitz Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-05-16 | 2013 | Steven W. Lefkowitz Interim Chief Financial Officer | 30,000 | 0 | 0 | 0 | 39,650 | 158,090 |
| 2014-05-16 | 2012 | Richard M. Cohen Interim Chief Executive Officer and Interim Chief Financial Officer | 86,250 | 0 | 0 | 0 | 0 | 125,450 |
| 2014-05-16 | 2013 | Richard M. Cohen Interim Chief Executive Officer and Interim Chief Financial Officer | 60,000 | 0 | 0 | 0 | 0 | 140,559 |
| 2014-05-16 | 2013 | Randy Milby Chief Executive Officer | 223,500 | 0 | 0 | 0 | 0 | 592,000 |
| 2013-06-20 | 2011 | Officer and Chief Financial Officer, Treasurer and Secretary | 250,000 | 0 | 0 | 0 | 0 | 250,000 |
| 2013-06-20 | 2012 | Officer and Chief Financial Officer, Treasurer and Secretary | 93,750 | 0 | 0 | 0 | 17,966 | 182,916 |
| 2013-06-20 | 2011 | Mark A. Klausner, M.D. Chief Medical Officer | 258,333 | 0 | 0 | 0 | 0 | 711,333 |
| 2013-06-20 | 2012 | Randy Milby Chief Operating Officer | 58,800 | 0 | 0 | 0 | 0 | 126,550 |
| 2013-06-20 | 2011 | Randy Milby Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-06-20 | 2012 | Mark A. Klausner, M.D. Chief Medical Officer | 180,833 | 0 | 0 | 0 | 7,556 | 188,389 |
| 2013-06-20 | 2012 | Interim Chief Executive Officer | 86,250 | 0 | 0 | 0 | 0 | 125,450 |
| 2013-06-20 | 2011 | Interim Chief Executive Officer | 22,500 | 0 | 0 | 0 | 31,500 | 104,900 |
| 2012-10-17 | 2010 | John C. Houghton Former President and Chief Executive Officer | 250,000 | 108,500 | 0 | 0 | 0 | 2,405,400 |
| 2012-10-17 | 2011 | Mark A. Klausner, M.D. | 258,333 | 0 | 0 | 0 | 0 | 711,333 |
| 2012-10-17 | 2011 | Richard M. Cohen | 54,000 | 0 | 0 | 0 | 0 | 104,900 |
| 2012-10-17 | 2011 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 36,667 | 0 | 0 | 0 | 0 | 36,667 |
| 2012-10-17 | 2010 | Brian Lenz Former Chief Operating Officer and Chief Financial | 175,000 | 84,760 | 0 | 0 | 0 | 1,078,560 |
| 2012-10-17 | 2011 | Brian Lenz Former Chief Operating Officer and Chief Financial | 250,000 | 0 | 0 | 0 | 0 | 250,000 |
| 2012-10-17 | 2009 | John C. Houghton Former President and Chief Executive Officer | 222,500 | 75,000 | 0 | 0 | 0 | 297,500 |
| 2012-10-17 | 2011 | John C. Houghton Former President and Chief Executive Officer | 350,000 | 0 | 0 | 0 | 0 | 350,000 |
| 2012-10-17 | 2009 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 220,000 | 0 | 0 | 0 | 0 | 220,000 |
| 2012-10-17 | 2010 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 220,000 | 51,084 | 0 | 0 | 0 | 1,089,884 |
| 2011-04-29 | 2009 | Mark T. Houser, M.D. Former Chief Medical Officer | 220,000 | 0 | 0 | 0 | 0 | 220,000 |
| 2011-04-29 | 2010 | Mark T. Houser, M.D. Former Chief Medical Officer | 220,000 | 51,084 | 0 | 0 | 0 | 1,089,884 |
| 2011-04-29 | 2010 | Brian Lenz Chief Financial Officer, Treasurer and Secretary | 175,000 | 84,760 | 0 | 0 | 0 | 1,078,560 |
| 2011-04-29 | 2009 | John C. Houghton President and Chief Executive Officer | 222,500 | 75,000 | 0 | 0 | 0 | 297,500 |
| 2011-04-29 | 2010 | John C. Houghton President and Chief Executive Officer | 250,000 | 108,500 | 0 | 0 | 0 | 2,405,400 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
